Moreover, combined therapy and thiopurine monotherapy resulted in a significantly higher proportion of patients with severe COVID-19 compared to TNF-antagonist monotherapy (8.8% and 9.2% vs. 2.2%, respectively, p < 0.001). This evidence concerns the gene TNF and COVID-19.